Novo Nordisk’s OpenAI Bet: Why the $600B Pharma Giant Just Handed Its Future to AI

The maker of Ozempic isn't building a chatbot. They're using OpenAI to compress a 15-year R&D cycle. Here’s what every industry must learn from this $600B pivot.